Literature DB >> 10493508

Characterization of the human Rad51 genomic locus and examination of tumors with 15q14-15 loss of heterozygosity (LOH).

C Schmutte1, G Tombline, K Rhiem, M M Sadoff, R Schmutzler, A von Deimling, R Fishel.   

Abstract

Human Rad51 (hRad51) has been found to be associated with BRCA1, BRCA2, and p53 either directly or indirectly and is one of at least eight human genes that are members of the Escherichia coli RecA/Saccharomyces cerevisiae Rad51 family thought to affect genomic stability through DNA recombination/repair processes. While inactivation of DNA mismatch repair clearly leads to instability of repeated sequences and to an increased risk for tumorigenesis, such a parallel for the RecA family members has not been reported. Recently, a high frequency of loss of heterozygosity at chromosome 15q14-15, near the genomic region containing hRad51, has been reported in human tumors (W. Wick et al., Oncogene, 12: 973-978, 1996). To determine whether hRad51 inactivation may be involved in the etiology of these tumors, we have characterized the hRad51 genetic locus and mapped it to chromosome 15q14-15 within the central region of loss of heterozygosity. However, single-strand conformational polymorphism analysis and direct sequencing of tumors did not reveal any mutations in the hRad51 coding sequence or intron/exon boundaries. We also examined the DNA methylation status of a CpG-rich region in the putative hRad51 promoter region. No indication of hypermethylation was found. These results suggest that hRad51 is not a tumor suppressor because it is either an essential gene, redundant gene and/or independent of the BRCA1/BRCA2 tumor suppressor pathway(s).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493508

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  RAD51 135G>C and TP53 Arg72Pro polymorphisms and susceptibility to breast cancer in Serbian women.

Authors:  Ana M Krivokuca; Emina J Malisic; Jelena D Dobricic; Ksenija V Brotto; Milena R Cavic; Radmila N Jankovic; Zorica I Tomasevic; Mirjana V Brankovic-Magic
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

Review 2.  BH3-only proteins and their effects on cancer.

Authors:  Thanh-Trang Vo; Anthony Letai
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

3.  Regulation of Rad51 promoter.

Authors:  Christopher M Hine; Hongjie Li; Li Xie; Zhiyong Mao; Andrei Seluanov; Vera Gorbunova
Journal:  Cell Cycle       Date:  2014-04-29       Impact factor: 4.534

4.  Use of the Rad51 promoter for targeted anti-cancer therapy.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-23       Impact factor: 11.205

Review 5.  BH3-only proteins in apoptosis and beyond: an overview.

Authors:  E Lomonosova; G Chinnadurai
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

Review 6.  Bim and Bmf in tissue homeostasis and malignant disease.

Authors:  J D Piñon; V Labi; A Egle; A Villunger
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

7.  Bcl2 family proteins in carcinogenesis and the treatment of cancer.

Authors:  Anna Frenzel; Francesca Grespi; Waldemar Chmelewskij; Andreas Villunger
Journal:  Apoptosis       Date:  2009-04       Impact factor: 4.677

8.  Inhibition of ERβ induces resistance to cisplatin by enhancing Rad51-mediated DNA repair in human medulloblastoma cell lines.

Authors:  Anna Wilk; Agnieszka Waligorska; Piotr Waligorski; Augusto Ochoa; Krzysztof Reiss
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

9.  Variation in the RAD51 gene and familial breast cancer.

Authors:  Felicity Lose; Paul Lovelock; Georgia Chenevix-Trench; Graham J Mann; Gulietta M Pupo; Amanda B Spurdle
Journal:  Breast Cancer Res       Date:  2006-06-08       Impact factor: 6.466

10.  Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development.

Authors:  Verena Labi; Miriam Erlacher; Stephan Kiessling; Claudia Manzl; Anna Frenzel; Lorraine O'Reilly; Andreas Strasser; Andreas Villunger
Journal:  J Exp Med       Date:  2008-02-25       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.